Predicting progression-free survival in hormone-receptor positive (HR+/HER2-) metastatic breast cancer (MBC) treated with CDK4/6 inhibitors: A machine learning approach
{{output}}
Background: In HR+/HER2- metastatic breast cancer (MBC), CDK4/6 inhibitors combined with endocrine therapy (ET) significantly improve progression-free survival (PFS). Machine learning (ML) approaches may improve individualized pr... ...
